Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

109.05 +0.35 (+0.32%)
Streaming Delayed Price Updated: 2:24 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
45 46 Next >
Blockbuster Drugs Market Projected to Show Strong Growth : Celgene, Bristol-Myers Squibb, Pfizer
Get an extensive Blockbuster Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
3 Biotech Stocks You Better Be Buying on Each and Every Dip
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there. 
Via InvestorPlace
2 Stocks That Raised Their Guidance in July
With inflation elevated, these are relatively resilient businesses to invest in. 
Via The Motley Fool
Should Income Investors Buy This Blue Chip Stock?
This Swiss drugmaker is one of the most dominant players in its industry. 
Via The Motley Fool
Why Novartis Stock Spiked Today
A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today. 
Via The Motley Fool
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
NVS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
DTx Pharma Acquisition by Novartis Generates Robust Returns for Tech Coast Angels and NuFund Venture Group
IRVINE, Calif. - Aug. 3, 2023 - PRLog -- Tech Coast Angels (TCA) and NuFund Venture Group (formerly TCA-San Diego) today announced that portfolio company DTx Pharma was acquired by Swiss pharmaceutical... 
Via PRLog
Novartis Puts Up Its Biggest Earnings Growth In Two Years; Shares Pop
Novartis put up more than 17.3% growth in its profit, beating quarterly records since June 2021. 
Via Investor's Business Daily
Earnings Preview For Novartis
Via Benzinga
Expert Opinions on Dry Eye Treatment Innovations
CRANBURY, N.J. - July 13, 2023 - PRLog -- IVIEW Therapeutics Inc. a clinical stage biotechnology company focusing on developing innovative ophthalmic therapeutics, organized a panel of dry eye experts... 
Via PRLog
Exposures Product Safety
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries
Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling  
Via Benzinga
The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos
With global events only rising in entropy, investors ought to consider these best dividend stocks for portfolio protection. 
Via InvestorPlace
AI for Pharma and Biotech Market May Set Massive Growth by 2030
Get a view on AI for Pharma and Biotech Market sales by marketing channels. Target important market by region and tap important dynamics of this industry. 
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
Week In Review: Novartis In $1 Billion Deal For DTx Pharma
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching... 
Via Talk Markets
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in 
Via Benzinga
Why Harrow Health Stock Is Trading Higher Today?
Harrow Health Inc (NASDAQ: HROW) agreed to acquire the U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a non‑preserved from Novaliq GmbH. 
Via Benzinga
Can Novartis Move to New Highs and Sustain Them?
Novartis stock is moving higher following outperformance in Q2 and increased guidance. A $15 billion share repurchase authorization is also in play. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Nasdaq Futures Rise As Focus Turns To Tesla, Netflix Q2 Prints: Analyst Says Earnings Need Some 'Heavy Lifting' For Sustained Rally
Via Benzinga
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
Wall Street Journal 
Via Benzinga
Novartis Q2 Earnings: Company Lifts Outlook, Launches $15B Share Buyback, Maps Out Sandoz Spin-Off
Novartis AG (NYSE: NVS) reported Q2 FY23 sales of $13.62 billion, up 7% Y/Y and 9% on constant currency, beating the consensus 
Via Benzinga
Nasdaq, S&P 500 Futures Dip Ahead of Big Bank Earnings, Retail Sales Data: Why This Analyst Stays Cautious About Tech Sector
Via Benzinga
Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Drug Maker Novartis Stock Shows Rising Relative Strength
Novartis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the preferred 80-plus score. 
Via Investor's Business Daily
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. 
Via Benzinga
S&P Makes Weekly Advance As Inflation Reaches Lowest Level Since March 2021; Amazon, Microsoft, Alphabet And Major Banks Lead Market Optimism
The S&P 500 is closing the week in the green in light of positive inflation data. The index was 2.48% higher on the week ahead of the market close Friday. Other major market indexes also showed an... 
Via Benzinga
Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight Loss
The company is hoping to curb the lean muscle mass loss tied to weight-loss drugs. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.